Economic analysis of zanubrutinib vs. acalabrutinib in B-cell malignancies

A recent meta-analysis by Hwang et al. provided a comprehensive comparison of adverse event (AE) profiles of zanubrutinib with acalabrutinib in patients with B-cell malignancies. Specific AEs seen more commonly with acalabrutinib than zanubrutinib included infections, atrial fibrillation, diarrhea, nausea/vomiting, headaches, cough, fatigue and pyrexia. On the other hand, hematuria, neutropenia, and hypertension were observed more frequently with zanubrutinib than with acalabrutinib [1]. Based on the AE profiles as reported by Hwang et al. and a health economic model developed from the UK’s National Health Service perspective, the costs and quality-of-life outcomes associated with the use of zanubrutinib vs. acalabrutinib were evaluated [2]. The investigators estimated the total cost of managing AEs by summing the costs of grade ≥ 3 and grade 1/2 AEs. The loss of quality-adjusted life years (QALY) for each AE was calculated by multiplying the incidence rates with the disutility weights assigned to them and their duration. Base-case, scenario and sensitivity analyses were conducted.

Cost savings & QALY benefits

In the base-case setting, considering all AEs, treatment of a hypothetical cohort of 1,000 patients with zanubrutinib instead of acalabrutinib led to cost savings of £ 599K and 3.7 QALY gains. The scenario analysis for grade ≥ 3 AEs and grade 1/2 AEs revealed similar trends for cost savings and QALY savings, with consistent results in a scenario analysis limited to AEs that were significantly different between the two drugs (Table). In both base-case and scenario analyses, the relative contribution of grade 1/2 AEs in cost savings was higher than that of grade ≥ 3 AEs, whereas QALY savings were similar among grade ≥ 3 and grade 1/2 AEs. According to the one-way sensitivity analysis, incidence rates for infections represented the most influential parameter affecting cost savings, whereas disutility associated with headache or infections on acalabrutinib treatment was the most influential parameter affecting QALYs. The results of the proba­bilistic sensitivity analysis supported the robustness of the findings.

Overall, this economic analysis demonstrated that in patients with B-cell malignancies, zanubrutinib therapy is cost-saving and associated with QALY benefits compared to acalabrutinib in terms of AE management. These results are consistent with an identical analysis conducted from a US perspective, according to which treatment of a hypothetical cohort of 1,000 patients with zanubrutinib instead of acalabrutinib resulted in cost savings of $ 124K and 3.7 QALY gains in the base-case scenario [3]. The sensitivity analysis and probabilistic sensitivity analysis confirmed the robustness of this model.

REFERENCES

  1. Hwang S et al., Comparison of treatment-emergent adverse events of acalabrutinib and zanubrutinib in clinical trials in B-cell malignancies: A systematic review and meta-analysis. EHA 2023, ab­stract P632
  2. Munir T et al., Zanubrutinib vs. acalabrutinib in B-cell malignancies: An adverse event-based economic analysis. EHA 2014, abstract S333
  3. Munir T et al., Comparison of zanubrutinib and acalabrutinib in B-cell malignancies: An adverse event-based analysis. J Clin Oncol 2024; 42 (suppl 16; abstr e19049)

© 2024 Springer-Verlag GmbH, Impressum

More posts

Relative efficacy of several treatment options in marginal zone lymphoma

Chemoimmunotherapy (CIT), immunotherapy and chemotherapy regimens are commonly used for the treatment of patients with marginal zone lymphoma. Moreover, the BTK inhibitor zanubrutinib has shown activity in the relapsed/refractory setting based on the phase II, single-arm MAGNOLIA and BGB-3111-AU-003 trials [1, 2]. Walewska et al. conducted a matching-adjusted indirect comparison (MAIC) to estimate the comparative efficacy of these treatment strategies in relapsed/refractory marginal zone lymphoma [3].

Follicular lymphoma: news on bispecific antibody treatment

In the setting of relapsed/refractory follicular lymphoma (FL), progression-free survival (PFS) deteriorates with successive relapses, which implies a high unmet need for therapies that can improve disease control and extend survival after relapse [1]. The Fc-silenced CD20 x CD3 bispecific antibody odronextamab is being investigated in patients with relapsed/refractory B-cell malignancies in the multicohort, multicenter, phase II ELM-2 study.

Innovative BCL2 inhibition: indications fanning out across B-cell malignancies

The combination of the first-generation BCL2 inhibitor venetoclax and the first-in-class BTK inhibitor ibrutinib has demonstrated efficacy in patients with chronic lymphocytic leukemia (CLL) [1], although tolerability of this regimen is limited. Next-generation agents can be expected to provide optimized toxicity profiles. The second-generation BCL2 inhibitor sonrotoclax inhibits BCL2 in a more selective and pharmacologically potent manner than venetoclax, with a shorter half-life preventing drug accumulation that might contribute to toxicity [2].

BTK degraders: emerging activity in various B-cell malignancies

The new class of BTK degraders is being developed in response to emerging patterns of resistance that limit the utility of BTK and BCL2 inhibitors. On one hand, BTK mutations decrease the efficacy of both covalent and non-covalent BTK inhibitors; on the other hand, some mutations lead to “kinase dead” or “kinase bypassing” BTK mutants with intact B-cell receptor signaling through a scaffolding function of BTK [1, 2].

Meeting unmet needs in mantle cell lymphoma

In older or unfit patients with mantle cell lymphoma (MCL), bendamustine plus rituximab (BR) is the most common first-line therapy, while intensive regimens are usually unsuitable in this population even though they provide durable responses [1, 2]. The addition of the first-in-class BTK inhibitor ibrutinib to first-line BR has been shown to prolong progression-free survival (PFS) in the SHINE trial [3].

Reducing risks further in chronic lymphocytic leukemia

The second-generation BTK inhibitor zanubrutinib is being tested in the phase III SEQUOIA trial in the setting of untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with and without del(17p). Zanubrutinib monotherapy has shown high tolerability and efficacy in arm C of the study that included patients with del(17p) [1].